Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
May 18 2020 - 4:30PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced the appointment of Matthew Walsh and Rachel
Stahler as Chief Financial Officer and Chief Information Officer,
respectively, for Organon & Co., its intended spinoff of its
women’s health, legacy brands and biosimilars businesses.
In his new role at Organon, Matt will be responsible for the
development and execution of the company’s overall financial
strategy, and will oversee corporate financial planning, tax,
audit, treasury, investor relations and business development. He
will join Organon from Allergan where he served as Executive Vice
President (EVP) and Chief Financial Officer (CFO). A seasoned
finance executive with over 15 years of public company CFO
experience, Matt has notable expertise in mergers and acquisitions,
including 11 acquisitions and integrations and five divestitures
during his nine-year tenure at Catalent where he served as EVP,
CFO.
Rachel will be responsible for all information technology
strategy, infrastructure, operations and delivery for Organon, and
will drive digital capabilities in support of the company’s
innovation strategy. Rachel also comes from Allergan, where she
recently served as Chief Information Officer (CIO). Rachel has
expertise in a broad range of information technology disciplines
with deep understanding of the development, manufacturing and
commercialization processes, having held roles in all three
domains. Prior to Allergan, Rachel held CIO positions in multiple
global health care organizations, including Pfizer, Syneos Health /
Inventiv Health and Optimer Pharmaceuticals.
“I am pleased to welcome Matt and Rachel to the recently
appointed Executive Leadership Team for Organon,” said Kenneth C.
Frazier, chairman and chief executive officer, Merck. “Their deep
expertise and pharmaceutical industry knowledge make them both
important additions to the team at this pivotal moment in Organon’s
preparation to become an independent company focused on positively
impacting the lives of patients and improving public health.”
“Rachel and Matt are proven leaders who understand the
complexities of a large global pharmaceutical business,” said Kevin
Ali, appointed chief executive officer of Organon. “I am confident
that we will benefit from their extensive experience, which will be
so critical to advancing Organon’s vision to be the world’s leading
women’s health company.”
The appointments of these two seasoned leaders mark another
important milestone as Merck prepares Organon to operate
independently. These appointments are in addition to the previously
named Organon Chairman of the Board Carrie Cox, and six internal
appointments to the Executive Leadership Team, announced in March
2020.
The spinoff transaction is on track for completion in the first
half of 2021. For further information, please visit
https://merck.unleashinggrowthpotential.com
About Merck
For more than 125 years, Merck, known as MSD outside of the
United States and Canada, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases in pursuit of our mission to save and improve
lives. We demonstrate our commitment to patients and population
health by increasing access to health care through far-reaching
policies, programs and partnerships. Today, Merck continues to be
at the forefront of research to prevent and treat diseases that
threaten people and animals – including cancer, infectious diseases
such as HIV and Ebola, and emerging animal diseases – as we aspire
to be the premier research-intensive biopharmaceutical company in
the world. For more information, visit www.merck.com and connect
with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200518005522/en/
Media: Jessica Fine (908) 740-1707 Kate Vossen (732) 675-8448
Investor: Peter Dannenbaum (908) 740-1037 Michael DeCarbo (908)
740-1807
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024